Overview

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Antibodies, Monoclonal
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate